Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)

The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.

NCT Number	NCT07625332
Lead Sponsor	Northwell Health Collaborators: Bronx Veterans Medical Research Foundation, Inc, Kessler Institute for Rehabilitation
Conditions	Spinal Cord Injury, Traumatic Spinal Cord Injury, Paraplegia and Tetraplegia, Metabolic Syndrome
Enrollment	60 participants
Start Date	2026-06-15
Primary Completion	2027-06 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-04